Victoza$526
Byetta$816
Wegovy$871
Trulicity$975
Ozempic$992
Rybelsus$995
Zepbound$1,052
Mounjaro$1,077
Saxenda$1,308
Victoza$526
Byetta$816
Wegovy$871
Trulicity$975
Ozempic$992
Rybelsus$995
Zepbound$1,052
Mounjaro$1,077
Saxenda$1,308

FDA warning letter: www.peacefulmeds.com

What the FDA told www.peacefulmeds.com in May 2025 about semaglutide — and whether it has been resolved.

By Sam Reed · Founder and data lead
What this letter is about
Selling a drug the FDA has not approved

The FDA says the company sold a drug that it has never approved for sale in the United States. Compounded semaglutide is the usual example: a compounded drug is legal to prescribe in specific circumstances, but it has not been through FDA approval, and selling it like an approved product is what the agency objects to.

FDA has also observed that www.peacefulmeds.com introduces into interstate commerce misbranded injectable semaglutide drug products.
FDA warning letter to www.peacefulmeds.com, MARCS-CMS 703470. Read it on fda.gov
Context

What an FDA warning letter is

It is a letter. The FDA writes to a company to say which of its practices the agency believes break the law, and asks it to fix them. That is the whole mechanism: a written notice, published so anyone can read it.

It is the FDA’s position, not a court’s finding. The company can reply, and can disagree. The agency states in these letters that failing to address the problems may lead to further action such as seizure or an injunction — which tells you the letter itself is not yet either of those things.

A warning letter does not recall a product, suspend a licence or close a business. It does not mean that medicine already dispensed was unsafe. When the FDA is satisfied the problems are fixed, it publishes a closeout letter.

What it does tell you is that a regulator looked at this company and wanted something changed. The useful question is what — and the quoted passage above answers it more precisely than any summary can.

The record

What the letter says

FieldWhat the letter statesSource
Recipientwww.peacefulmeds.comFDA warning letter
IssuedMay 5, 2025FDA warning letter
Issuing officeCenter for Drug Evaluation and Research (CDER)FDA warning letter
FDA referenceMARCS-CMS 703470FDA warning letter
LocationUnited StatesFDA warning letter
SubjectUnlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the InternetFDA warning letter
What it concernsSelling a drug the FDA has not approvedRead from the subject line
Medication namedSemaglutideLetter text
StatusOpen — no closeout letter publishedFDA warning letter list
Data sources · cited with retrieval dates

NADAC figures are pharmacy acquisition costs, not retail prices and not what you will pay. This content is educational and is not medical advice.